260 related articles for article (PubMed ID: 21469439)
1. Inhibition of galectins with small molecules.
Oberg CT; Leffler H; Nilsson UJ
Chimia (Aarau); 2011; 65(1-2):18-23. PubMed ID: 21469439
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.
Porciúncula González C; Cagnoni AJ; Mariño KV; Fontana C; Saenz-Méndez P; Irazoqui G; Giacomini C
Carbohydr Res; 2019 Jan; 472():1-15. PubMed ID: 30428394
[TBL] [Abstract][Full Text] [Related]
3. Linear triazole-linked pseudo oligogalactosides as scaffolds for galectin inhibitor development.
Dussouy C; Kishor C; Lambert A; Lamoureux C; Blanchard H; Grandjean C
Chem Biol Drug Des; 2020 Oct; 96(4):1123-1133. PubMed ID: 32220037
[TBL] [Abstract][Full Text] [Related]
4. Rational Design and Synthesis of Methyl-β-d-galactomalonyl Phenyl Esters as Potent Galectin-8
Patel B; Kishor C; Houston TA; Shatz-Azoulay H; Zick Y; Vinik Y; Blanchard H
J Med Chem; 2020 Oct; 63(20):11573-11584. PubMed ID: 32809817
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of a phenyl thio-beta-D-galactopyranoside library from 1,5-difluoro-2,4-dinitrobenzene: discovery of efficient and selective monosaccharide inhibitors of galectin-7.
Cumpstey I; Carlsson S; Leffler H; Nilsson UJ
Org Biomol Chem; 2005 May; 3(10):1922-32. PubMed ID: 15889175
[TBL] [Abstract][Full Text] [Related]
6. Galectin binding to cells and glycoproteins with genetically modified glycosylation reveals galectin-glycan specificities in a natural context.
Nielsen MI; Stegmayr J; Grant OC; Yang Z; Nilsson UJ; Boos I; Carlsson MC; Woods RJ; Unverzagt C; Leffler H; Wandall HH
J Biol Chem; 2018 Dec; 293(52):20249-20262. PubMed ID: 30385505
[TBL] [Abstract][Full Text] [Related]
7. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography.
Hirabayashi J; Hashidate T; Arata Y; Nishi N; Nakamura T; Hirashima M; Urashima T; Oka T; Futai M; Muller WE; Yagi F; Kasai K
Biochim Biophys Acta; 2002 Sep; 1572(2-3):232-54. PubMed ID: 12223272
[TBL] [Abstract][Full Text] [Related]
8. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.
Vladoiu MC; Labrie M; Létourneau M; Egesborg P; Gagné D; Billard É; Grosset AA; Doucet N; Chatenet D; St-Pierre Y
Oncotarget; 2015 Dec; 6(38):40970-80. PubMed ID: 26543238
[TBL] [Abstract][Full Text] [Related]
9. Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138.
Su J; Wang Y; Si Y; Gao J; Song C; Cui L; Wu R; Tai G; Zhou Y
Sci Rep; 2018 Jan; 8(1):980. PubMed ID: 29343868
[TBL] [Abstract][Full Text] [Related]
10. Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors.
Hsieh TJ; Lin HY; Tu Z; Lin TC; Wu SC; Tseng YY; Liu FT; Hsu ST; Lin CH
Sci Rep; 2016 Jul; 6():29457. PubMed ID: 27416897
[TBL] [Abstract][Full Text] [Related]
11. Inhibition mechanism of human galectin-7 by a novel galactose-benzylphosphate inhibitor.
Masuyer G; Jabeen T; Öberg CT; Leffler H; Nilsson UJ; Acharya KR
FEBS J; 2012 Jan; 279(2):193-202. PubMed ID: 22059385
[TBL] [Abstract][Full Text] [Related]
12. Benzimidazole-galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation.
Hassan M; van Klaveren S; Håkansson M; Diehl C; Kovačič R; Baussière F; Sundin AP; Dernovšek J; Walse B; Zetterberg F; Leffler H; Anderluh M; Tomašič T; Jakopin Ž; Nilsson UJ
Eur J Med Chem; 2021 Nov; 223():113664. PubMed ID: 34225180
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of stable and selective inhibitors of human galectins-1 and -3.
Giguère D; Bonin MA; Cloutier P; Patnam R; St-Pierre C; Sato S; Roy R
Bioorg Med Chem; 2008 Aug; 16(16):7811-23. PubMed ID: 18674915
[TBL] [Abstract][Full Text] [Related]
14. Immunoprotective neo-glycoproteins: Chemoenzymatic synthesis of multivalent glycomimetics for inhibition of cancer-related galectin-3.
Heine V; Hovorková M; Vlachová M; Filipová M; Bumba L; Janoušková O; Hubálek M; Cvačka J; Petrásková L; Pelantová H; Křen V; Elling L; Bojarová P
Eur J Med Chem; 2021 Aug; 220():113500. PubMed ID: 33962190
[TBL] [Abstract][Full Text] [Related]
15. Binding and cross-linking properties of galectins.
Fred Brewer C
Biochim Biophys Acta; 2002 Sep; 1572(2-3):255-62. PubMed ID: 12223273
[TBL] [Abstract][Full Text] [Related]
16. Arginine binding motifs: design and synthesis of galactose-derived arginine tweezers as galectin-3 inhibitors.
Oberg CT; Leffler H; Nilsson UJ
J Med Chem; 2008 Apr; 51(7):2297-301. PubMed ID: 18318467
[TBL] [Abstract][Full Text] [Related]
17. Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
Wdowiak K; Francuz T; Gallego-Colon E; Ruiz-Agamez N; Kubeczko M; Grochoła I; Wojnar J
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29320431
[TBL] [Abstract][Full Text] [Related]
18. Galectins: novel anti-inflammatory drug targets.
Liu FT
Expert Opin Ther Targets; 2002 Aug; 6(4):461-8. PubMed ID: 16353421
[TBL] [Abstract][Full Text] [Related]
19. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells.
Patnaik SK; Potvin B; Carlsson S; Sturm D; Leffler H; Stanley P
Glycobiology; 2006 Apr; 16(4):305-17. PubMed ID: 16319083
[TBL] [Abstract][Full Text] [Related]
20. 3-(1,2,3-Triazol-1-yl)-1-thio-galactosides as small, efficient, and hydrolytically stable inhibitors of galectin-3.
Salameh BA; Leffler H; Nilsson UJ
Bioorg Med Chem Lett; 2005 Jul; 15(14):3344-6. PubMed ID: 15963723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
